New Strategies in Breast Cancer: The Significance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T1a,bN0M0 Tumors

被引：14
|
作者：
Sonnenblick, Amir [1 ,2 ]
Fumagalli, Debora [2 ]
Azim, Hatem A., Jr. [1 ]
Sotiriou, Christos [2 ]
Piccart, Martine [1 ]
机构：
[1] Univ Libre Bruxelles, Inst Jules Bordet, Dept Med, BrEAST Data Ctr, Brussels, Belgium
[2] Univ Libre Bruxelles, Inst Jules Bordet, Breast Canc Translat Res Lab, Brussels, Belgium
来源：
CLINICAL CANCER RESEARCH | 2014年 / 20卷 / 24期
关键词：
GENE-EXPRESSION; INFILTRATING LYMPHOCYTES; DISTANT RECURRENCE; TISSUE FIXATION; TRASTUZUMAB; CHEMOTHERAPY; RISK; PROGNOSIS; SURVIVAL; WOMEN;
D O I：
10.1158/1078-0432.CCR-14-1086
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Awareness of breast cancer heterogeneity has strikingly increased in the past decade in parallel with the development of high-throughput molecular tests. Beyond the clear usefulness of antiestrogen treatment in luminal tumors and trastuzumab in HER2-positive tumors, breast cancer subtypes may have additional clinical and predictive roles that can be relevant to clinical practice. In this article, we discuss the significance of molecular subtypes in the systemic treatment of early-stage breast tumors smaller than 1 cm (T1a,bN0M0) and suggest new strategies for future treatment recommendations for these patients. (C) 2014 AACR.
引用
收藏
页码：6242 / 6246
页数：5
相关论文
共 50 条
  • [21] Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debate
    Fausto Petrelli
    Sandro Barni
    [J]. Medical Oncology, 2011, 28 : 401 - 408
  • [22] Prognosis of T1bN0M0 breast cancer in patients receiving breast conservation therapy.
    VanderVelde, N
    Decker, DA
    Vicini, F
    Mitchell, C
    Huang, R
    Zakalik, D
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 266 - 266
  • [23] Treatment Trends and Factors Associated with Survival in T1aN0 and T1bN0 Breast Cancer Patients
    Timothy Kennedy
    Andrew K. Stewart
    Karl Y. Bilimoria
    Lina Patel-Parekh
    Stephen F. Sener
    David P. Winchester
    [J]. Annals of Surgical Oncology, 2007, 14 : 2918 - 2927
  • [24] Treatment trends and factors associated with survival in T1aN0 and T1bN0 breast cancer patients
    Kennedy, Timothy
    Stewart, Andrew K.
    Bilimoria, Karl Y.
    Patel-Parekh, Lina
    Sener, Stephen F.
    Winchester, David P.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (10) : 2918 - 2927
  • [25] Adjuvant chemotherapy in T1a/bN0 breast cancer patients with high oncotype DX recurrence scores (RS>25)
    Katz, D.
    Feldhamer, I.
    Hammerman, A.
    Goldvaser, H.
    Goldstein, D.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S284 - S284
  • [26] Locoregional treatment and overall survival of men with T1a,b,cN0M0 breast cancer: A population-based study
    Leone, Jose Pablo
    Leone, Julieta
    Zwenger, Ariel Osvaldo
    Iturbe, Julian
    Amadeo Leone, Bernardo
    Teodoro Vallejo, Carlos
    [J]. EUROPEAN JOURNAL OF CANCER, 2017, 71 : 7 - 14
  • [27] Impact of Detection Method and Accompanying Ductal Carcinoma in Situ on Prognosis of T1a,bN0 Breast Cancer
    Shen, Shih-Che
    Ueng, Shir-Hwa
    Yang, Chan-Keng
    Yu, Chi-Chang
    Lo, Yung-Feng
    Chang, Hsien-Kun
    Lin, Yung-Chang
    Chen, Shin-Cheh
    [J]. JOURNAL OF CANCER, 2017, 8 (12): : 2328 - 2335
  • [28] Pooled Analysis of Outcomes of T1a/bN0, HER2-Amplified Breast Cancer.
    Amir, E.
    Seruga, B.
    Ocana, A.
    Carlsson, L.
    Bedard, P.
    [J]. CANCER RESEARCH, 2011, 71
  • [29] The Survival Outcomes of T1aN0M0 Triple-Negative Breast Cancer With Adjuvant Chemotherapy
    Fu, Wen-Fen
    Chen, Qing-Xia
    Wang, Xiao-Xiao
    Zhang, Jie
    Song, Chuan-Gui
    [J]. FRONTIERS IN ONCOLOGY, 2020, 10
  • [30] Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer
    Ren, Yi-Xing
    Hao, Shuang
    Jin, Xi
    Ye, Fu-Gui
    Gong, Yue
    Jiang, Yi-Zhou
    Shao, Zhi-Ming
    [J]. BREAST, 2019, 43 : 97 - 104
12345